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TISSUE OXYGENATION WITH 
GRADED DISSOLVED 
OXYGEN DELIVERY DURING 
CARDIOPULMONARY 
BYPASS 
Background: Intravascular perfluorochemical emulsions together with a 
high oxygen tension may increase the delivery of dissolved oxygen to useful 
levels. The hypothesis of this study is that increasing the dissolved oxygen 
content of blood with incremental doses of a perfluorochemical emulsion 
improves tissue oxygenation during cardiopulmonary b pass in a dose-related 
fashion. Methods and Results: Oxygen utilization was studied in a profoundly 
anemic anine model of hypothermic cardiopulmonary b pass. Forty-two dogs 
underwent normovolemic hemodilution to a hematocrit of 15.8% _ 0.6% 
(mean -+ standard error of the mean). Cardiopulmonary bypass was begun 
and resulted in a hematocrit of 9.4% +- 0.6%. A standard priming solution was 
used in the control group (n = 12), and the test groups received 1.35 gm 
perfluorochemical • kg -1 (n = 10 dogs), 2.7 gm perflnorochemical • kg -1 (n = 
10 dogs), or 5.4 gm perfluorochemical • kg -1 (n = 10 dogs) through the venous 
return cannula. Each animal underwent a series of randomized pump flows 
(0.25, 0.5, 1.0, 1.5, 2.0, and 3.0 L .  min -1.  m -2) at 32 ° C. After the randomized 
flows were completed at 32 ° C, the temperature was raised to 38 ° C and 
cardiopulmonary b pass was discontinued. Mortality from cardiac failure on 
separation from cardiopulmonary b pass was 42% in the control group and 
20% in perfluorochemical-treated groups. The mean perfluorochemical dose 
was higher in survivors than in nonsurvivors (2.9 _ 0.4 versus 1.3 -+ 0.5 gm 
perfluorochemical, kg- l ;  p < 0.05). No differences in oxygen consumption or 
transbody lactate gradient were found between groups during cardiopulmo- 
nary bypass. Analysis of mixed venous oxygen tension (a surrogate measure for 
tissue oxygenation) as a function of cardiopulmonary b pass flow normalized 
to body surface area showed that the control group had significantly lower 
mixed venous oxygen tension (17 < 0.05) than the perfluorochemical emulsion- 
treated groups. Furthermore, the differences were related to the perfluoro- 
chemical emulsion dose. These differences in mixed venous oxygen tension 
continued after termination of cardiopulmonary b pass. The coronary sinus 
oxygen tension and cardiac arterial-venous oxygen content differences during 
and after cardiopulmonary bypass were similar among the control and 
perfluorochemical emulsion-treated animals. Dissolved oxygen consumption 
during and after cardiopulmonary b pass was calculated. Dissolved oxygen 
consumption i creased in the perfluorochemical-treated nimals in a perfluo- 
rochemical dose-related manner and was significantly higher in perfluoro- 
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chemical-treated animals than in the control animals (p < 0.05). Conclusions: 
Graded increases in mixed venous oxygen tension during cardiopulmonary bypass 
were observed in response to graded increases in the dissolved oxygen delivery. 
These data suggest that enhancing oxygenation with perfluorochemical-dissolved 
oxygen is an effective temporary substitute for the use of hemoglobin-bound oxygen 
during cardiopulmonary bypass. Perfluorochemical-dissolved oxygen may be par- 
ticularly beneficial in the setting of multiple hypoxic stresses. (J THORAC CARDIO- 
VASe SURG 1995;110:774-85) 
O xygen de.livery during total cardiopulmonary b - pass (CPB) is dependent on perfusate oxygen 
content and pump flow. Perfusate oxygen content is 
primarily dependent on the concentration of hemo- 
globin with only a small contribution from physically 
dissolved oxygen in the plasma. 
Perfluorochemicals (PFCs) have a high intrinsic 
solubility for oxygen. The recent development of 
novel high-concentration (e.g., 90% to 100% wt/vol) 
PFC emulsions in theory can substantially increase 
the volume of physically dissolved oxygen that is 
carried in the blood. 1' 2 Dissolved oxygen in plasma 
obeys Henry's law, which states that the mass of gas 
that dissolves in a liquid is directly proportional to 
the partial pressure of that gas. The relationship of 
dissolved oxygen content in blood and Po2 is there- 
lore linear, in contrast o the sigmoidal relationship 
for hemoglobin oxygen content and Po 2. In addition, 
unlike for hemoglobin-bound oxygen, the availabil- 
ity of dissolved oxygen for diffusive transport o 
tissues is unaffected by changes in pH or tempera- 
ture. 
The purpose of this study was to measure tissue 
oxygenation, as represented by the Po 2 in mixed 
venous blood, during hypothermic CPB with graded 
concentrations of dissolved oxygen in the perfusate. 
The hypothesis tested was that increasing the dis- 
solved oxygen content of blood with incremental 
doses of a PFC emulsion improves tissue oxygen- 
ation during CPB in a dose-related fashion. 
Methods 
Oxygen metabolism was studied in a profoundly anemic 
(i.e., hematocrit of approximately 10% during bypass) 
canine m0del of hypothermic CPB. The experimental 
protocol we describe was approved by the University of 
Alabama at Birmingham Animal Use Review Committee 
and met the standards outlined by the American Physio- 
logical SocieVy and the National Institutes of Health in the 
"Guide for the Care and Use of Laboratory Animals" 
(NIH puNication No. 85-23, revised 1985). 
Experimental variables. The biochemical variables 
measured in this study included (1) systemic arterial, 
mixed venous, and coronary sinus blood gas values, oxy- 
gen content, and hemoglobin saturations; and (2) systemic 
arterial, mixed venous, and coronary sinus lactate concen- 
tration. Oxygen content was measured with a Lex-O2-Con 
device (Hospex Fiberoptics, Inc., Chestnut Hill, Mass.). 
Blood gas and hemoglobin saturation determinations 
were made witb a pH-blood gas analyzer (model 238, 
Ciba-Corning Diagnostics Ltd., Halstead, Essex, England) 
and a co-oximeter (IL model 282, Instrumentation Labo- 
ratory Co., Norcross, Ga.). Lactate determinations were 
made with an analyzer (COBAS-FARA II, Roche Diag- 
nostic Systems, Montclair, N.J.). 
The hemodynamic variables included (1) systemic and 
pulmonary artery blood pressures (phasic and mean), (2) 
left atrial pressure (mean), and (3) cardiac output (ther- 
modilution). Hemodynamic and electrocardiographic 
data were digitized and stored on hard drive or magneto- 
optical disk for subsequent analysis. 
Other measured variables included pelfusate and 
esophageal temperatures, bypass flow rate (calibrated 
roller pump), wet and dry myocardial tissue weights 
(obtained post mortem), hematocrit-fluorocrit (perfluoro- 
carbon emulsion settles as a distinct layer at the bottom of 
a spun blood sample), and blood samples at end of bypass 
and at end of study (3 to 5 ml whole blood in ethylenedia- 
minetetraacetic acid, stored frozen) for perfluorocarbon 
content analysis by gas chromatography. 
Derived variables included cardiac arterial-venous oxy- 
gen content difference (AVO 2 difference), total body 
oxygen consumption, cardiac and total body lactate gra- 
dient, and partitioning of total oxygen consumption i to 
hemoglobin-bound and dissolved oxygen components. 
Surgical and pump-oxygenator p otocol. A total of 42 
mixed-breed dogs weighing from 25 to 30 kg were in- 
cluded in this study. The initial surgical and anesthetic 
management was as follows. The animals were anesthe- 
tized with sodium pentobarbital, plaeed on a heating 
blanket, and intubated, and their lungs were ventilated 
with 100% oxygen. Pancuronium bromide was given after 
an adequate level of anesthesia was assured, and an 
infusion of sodium pentobarbital nd paneuronium was 
used to maintain anesthesia. 
Limb electrocardiographic leads and an esophageal 
temperature probe were place& The femoral vessels, 
carotid artery, and external jugular vein were exposed. An 
arterial pressure-monitoring catheter, a thermodilution 
right heart catheter, and fluid infusion lines were placed. 
A laparotomy was performed. Epinephrine was injected 
through the splenic artery; then the contracted spleen was 
removed. The laparotomy was closed, and a median 
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sternotomy was made. Catheters for blood sampling were 
placed in the main pulmonary artery and in the mid 
portion of the coronary sinus. A pressure monitoring 
catheter was placed in the left atrium. 
The baseline hematocrit was measured, and the dog's 
total blood volume (TBV) was calculated by using the 
formula: 
TBV = [92.6 ta l '  kg -1] [Weight (kg)] 
Heparin was administered (300 U/kg), and the animal 
was normovolemically hemodiluted to a 'hematocrit of 
approximately 15% by using a constant mean left atrial 
pressure as an indicator of vascular volume. The volume 
of crystalloid solution administered was calculated as 
[- Hct ] 
Amount diluent added (ml) = - TBV. ln [~]  
where Hct = final hematocrit and HCt»as« = initial hema- 
tocrit. The replacement fluid for blood was 38 ° C normal 
saline solution with 50 mEq. L 1 NaHCO3 and 5 
mEq- L-1 KC1 added. 
The pump oxygenator circuit used right atrial and 
femoral arterial cannulation. The left ventricle was 
vented. The oxygenator was a hollow fiber device (Max- 
ima, Medtronic, Inc., Minneapolis, Minn.). A hollow fiber 
oxygenator design was chosen on the basis of a previous 
study that demonstrated significantly higher oxygen trans- 
fer rates to PFC emulsions for hollow fiber and true 
membrane oxygenators than for bubble oxygenators. 3 
The oxygenator was gassed with oxygen at twice the 
blood flow, and CO2 was blended with the sweep oxygen 
as needed to maintain Pco2 within physiologic fange. The 
pump priming solution contained 660 ml Normosol-R, pH 
7.4 (Abbott Laboratories, North Chicago, Ill.), 330 ml 5% 
dextrose in water, and 10 ml 1 mEq. m1-1 NaHCO 3. 
Experimental data acquisition protocol. After the sple- 
nectomy and line placement were completed, prehemodi- 
lution data were acquired. The animals were then normo- 
volemically hemodiluted, and posthemodilution data were 
obtained. CPB was initiated at 38 ° C, a Po2 >500 mm Hg, 
and a flow of 2.0 L-min -1. m -2. At this time, control 
animals (n = 12) had no addition to the oxygenator, whereas 
the test groups had PFC 1.35 grn. kg 1 (n = 10 dogs), PFC 
2.7 gin' kg -1 (n = 10 dogs), or PFC 5.4 gin- kg -1 (n = 10 
dogs) added through the venous return cannula. The PFC 
emulsion was a 90% wt/vol emulsion based on perflubron 
(perfluorooctyl bromide) (Oxygent [AF0142], Allianee Phar- 
maceutieal Corp., San Diego, Calif.). 
Initial blood samples were drawn 5 minutes after ran- 
domization and PFC dosing. The water bath was cooled to 
32 ° C; after 10 minutes a series of randomized pump flows 
(0.25, 0.5, 1.0, 1.5, 2.0, and 3.0 L 'min  1.m-2)  was 
begun. Each flow was run for 5 minutes before blood 
samples and hemodynamic data were obtained. After the 
randomized flows were comPaleted at 32 ° C, flow was 
resumed at 2.0 L.  min -1 • m-  , and the temperature was 
raised to 38 ° C for 20 minutes. Hemodynamic data and 
blood samples were obtained. CPB was terminated. By 
protocol restriction, no inotropic agents were used. The 
pre-CPB mean left atrial pressure was used as a guide for 
the post-CPB left atrial pressure; however, if the systemic 
blood pressure and cardiac output were inadequate, the 
left atrial pressure was increased as high as 20 mm Hg in 
an attempt o discontinue CPB. Blood samples and he- 
modynamic data were acquired at the termination of CPB 
and every 15 minutes for 1 hour after CPB. After CPB, 
crystalloid or whole blood was administered as needed to 
maintain a hematocrit of 10% to 12% and a constant 
mean left atrial pressure. No additional PFC emulsion was 
given during the study even if the fluorocrit decreased. 
The animals were then killed. The hearts were removed 
and weighed, and sections of the left ventricle were 
obtained for weighing and desiccation. 
Statistical analysis. The data were analyzed by using 
SAS-PC software (SAS Institute, Inc., Cary, N.C.), then 
displayed by using Sigma Plot software (Jandel Scientific, 
Corte Madera, Calif.). Statistical comparisons of hemody- 
namic data, hematocrit, fluorocrit, and biochemical data 
were made with analysis of variance designs (i.e., Dun- 
can's multiple-range t st and least-squares means test) 
contained in the General Linear Models procedure of 
SAS-PC. Duncan's multiple-range t st was used to statis- 
tically define differences between groups when multiple 
groups were being simultaneously compared. 4 The least- 
squares means test was used for individual between-group 
comparisons. 4 The level of significance chosen for this 
study was p < 0.05. 
Comparisons of mixed venous Po2 (Pvo2), serum lac- 
tate, and total body oxygen consumption during CPB were 
made by first plotting the experimental variable as a 
function of oxygen delivery rate or CPB flow normalized 
to the animal's body surface area .  4" 5 The data were then 
fit to functions, and the parameters of the equations were 
compared between the four experimental groups by using 
Duncan's multiple-range t st for comparisons between 
multiple groups and the least-squares means test for 
individual between-group comparisons. (See Appendix 1 
for a description of methods used to determine optimal 
curve fit and calculate variance.) 
Results 
Normovolemic hemodilution before CPB resulted 
in a decrease in the hematocrit  to 15.8% _+ 0.6% (all 
values are given as mean _+ SEM*). Initiation of CPB 
with a crystalloid priming solution further decreased 
the hematocrit to 9.4% _+ 0.6% (Table I). No statisti- 
cally significant differences were found in hematocrit  
between groups throughout the study. The fluorocrits 
of the treated groups reflect he dose of PFC emulsion 
the animals received (Table II). The gas chromato- 
graphic analysis of blood PFC content corroborated 
the relative amounts of PFC detected by the fluorocrit 
in the four experimental groups (Table III). The 
fluorocrit remained constant during CPB and de- 
creased after CPB. 
The animals responded to hemodi lut ion with an 
increase in cardiac output. No significant differences 
*Standard error of the mean. 
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Table I. Hematocrits in the three groups before and after hemodilution and during and after CPB 
Hematocrit (%) 
60 min 
Groups Before HD After HD During CPB After CPB after CPB 
Control  51.5 -+ 1.9 16.0 -4- 0.6 9.9 _+ 0.4 13.4 _+ 0.6 11.9 _+ 1.0 
1.35 gm PFC.kg 1 55.2 _+ 1.4 16.5 -4- 0.5 9.8 _+ 0.3 12.5 _+ 0.4 11.6 _+ 0.5 
2.7 gm PFC.kg -1 45.4 _+ 2.6 15.8 -+ 0.5 9.1 _+ 0.7 13.7 _+ 1.1 11.8 _+ 0.8 
5.4 gm PFC-kg -1 50.0 + 1.7 14.8 + 0.7 8.6 -+ 0.8 13.5 _+ 0.7 12 _+ 1.1 
Values are expressed as mean -+ standared error of the mean. There were no significant differences between groups. Before HD, Before hemodilution; After 
HD, after hernodilution before CPB; After CPB, at termination of CPB; 60 min after CPB, 60 minutes after termination of CPB. 
Table II. Fluorocrits of the three groups before and after hemodilution and during and after CPB 
Fluorocrit (%) 
60 min 
Groups Before HD After HD During CPB After CPB after CPB 
Control  0 0 0 0 0 
1.35 gm PFC-  kg -1 0 0 1.1 +_ 0.1 1.2 _+ 0.1 1.0 _+ 0.1 
2.7 gm PFC '  kg -1 0 0 2.0 _+ 0.1 1.9 +_ 0.1 1.25 _+ 0.2 
5.4 gm PFC.  kg -1 0 0 3.1 _+ 0.1 3.1 _+ 0.2 2.1 _+ 0.2 
Values are expressed as mean -+ standard error of the mean. The fluorocrits of the PFC emulsion groups remained stable throughout CPB and decreased 
during the initial 60 minutes after CPB. Before HD, Before hemodilution; After liD, after hemodilution before CPB; After CPB, at termination of CPB; 60 
min after CPB, 60 minutes after termination of CPB. 
Table III. Blood perftuorocarbon concentration after CPB as determined by gas chromatography 
Blood PFC concentration (ixg. m1-1) 
Time off CPB (min) 1.35 grn PFC " kg ~ group 2.7 grn PFC . kg -1 group 5.4 gm PFC . kg -~ group 
0 8,394 _+ 474 (n = 10) 15,257 _+ 1,149 (n = 8) 32,420 _+ 2,032 (n = 5) 
60 6,631 _+ 237 (n = 5) 12,801 _+ 1,002 (n = 6) 25,156 _+ 5,212 (n = 4) 
Values are expressed as mean -+ standard error of the mean. Actual number of determinations for each sampling group is given in parentheses. 
Perfluorocarbon content of blood in control group was below detectable imit. 
were observed between groups in pre-CPB or post- 
CPB cardiac index. During the post-CPB period, 
five of the untreated animals died and five of the 
animals that received an emulsion dose of 1.35 gm 
PFC" kg -1 died. Only two of the animals given a 2.7 
gm-kg -1 PFC emulsion dose and one given a 5.4 
gm. kg -1 PFC emulsion dose died. All deaths were 
a result of post-CPB circulatory failure (i.e., low 
cardiac output). Fig. 1 shows the Kaplan-Meier 
estimate for death during the first hour after CPB. A 
trend was found toward a lower incidence of death 
at 1 hour after CPB as the dose of PFC increased 
(p = 0.065). Furthermore, the mean PFC emulsion 
dose in survivors was significantly higher than in 
nonsurvivors (PFC 2.6 _+ 0.4 gm. kg -1 versus PFC 
1.2 _+ 0.5 gm-kg-~; p < 0.05). 
Measurements of total hemoglobin content and 
oxyhem0globin saturation were complicated some- 
what by PFC emulsion turbidity. This effect has been 
noted by others and can cause errors of _+10% in 
readings. 6 Rather than using measurements of he- 
moglobin saturation from the oximeter, we calcu- 
lated oxyhemoglobin saturation with equations de- 
veloped by Rossing and Cain. 7 These calculated 
values were used to evaluate venous Po 2 as a 
function of hemoglobin oxygen delivery. Consistent 
between-group differences in the functions defining 
Pvo 2 versus hemoglobin oxygen delivery were not 
demonstrated when the method of Rossing and 
Cain was used to calculate oxyhemoglobin satura- 
tion. 
Total oxygen delivery and oxygen consumption 
were calculated from perfusate oxygen content as 
measured by a fuel cell (i.e., the Lex-O2-Con de- 
vice). The fuel cell is insensitive to the turbidity of 
PFC emulsions because it measures oxygen content 
by a chemical reaction. No differences were found in 
oxygen consumption (Fig. 2) between groups during 
778 Holman et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
September 1995 
1.0 ¸  
0.9 
o 0.8 
~ 0,7 
~ @.6 
,~ 0.5 
~ 0.4 
.~ o.3 
> 
~ 0.2 
0.1 
F PFC-HIGH 
- 
" ,  
"ù  
PFC-M[D J
ù. 
ù. 
PFC-L0WJ  
0 .0  ~ r 1 I I 
0 10 20 30 40 50 60 
T ime Post -CPB (minutes) 
Fig. 1. Survival function estimate for groups. Kaplan- 
Meier depiction for death after CPB. A higher incidence 
of death was seen at 1 hour after CPB as the dose of PFC 
decreased (p = 0.065 by logistic regression analysis). 
PFC-HIGH, PFC 1.35 gm. kg -a (n = 10 dogs);PFC-MID, 
PFC 2.7 gin. kg -a (n = 10 dogs); PFC-LOW, PFC 5.4 
gin" kg -1 (n = 10 dogs). 
CPB, as measured by fuel cell determinations of
AVO 2 difference and pump flow. 
Analysis of Pvo2 as a function of CPB flow 
normalized to animal body surface area is shown in 
Fig. 3. The regression equation that describes this 
function is shown in Appendix 2. The control group 
was significantly different (p < 0.05) from the PFC 
emulsion-treated groups. Furthermore, the differ- 
ences were dose related. 
The Pvo 2 values for the four groups were then 
expressed as a function of oxygen delivery during 
CPB (Fig. 4 and Appendix 2). This analysis accounts 
for the effects of additional dissolved oxygen in the 
PFC emulsion-treated animals and for any animal- 
to-animal variance in hemoglobin concentration; 
thus it was anticipated that the four curves would be 
similar. The b coefficients were similar; however, 
there is a higher intercept (i.e., a value) for the three 
PFC emulsion-treated groups as compared with the 
control group. The p values ranged from 0.025 to 
0.09 for individual PFC emulsion group versus con- 
trol group comparisons. If the data for the three 
PFC emulsion groups are combined and compared 
with data for the control animals to examine for a 
PFC emulsion effect, a significant difference is seen 
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Fig. 2. Total body oxygen consumption during CPB was 
not significantly different between groups. Normalized 
pump flow is CPB flow normalized to body surface area. 
PFC-HIGH, PFC 1.35 gin. kg -1 (n = 10 dogs); PFC-MID, 
PFC 2.7 gin" kg -1 (n = 10 dogs); PFC-LOW, PFC 5.4 
gm. kg -1 (n = 10 dogs). 
between control and PFC emulsion animals (p < 
0.002) (Fig. 5). This finding suggests that PFC- 
dissolved oxygen exerted a sparing effect on hemo- 
globin-bound oxygen. 
The portion of total oxygen delivery and con- 
sumption attributable to dissolved oxygen was cal- 
culated. This calculation was based on blood PFC 
content as measured by gas chromatography (Table 
III), Po2, and the solubility coetticient for oxygen in 
perfluorooctyl bromide (oxygen 50 rel. dl -1 at 38 ° C 
and 1 atm pressure). A depiction of dissolved oxy- 
gen consumption during and after CPB shows a 
significant increase in dissolved oxygen consumption 
for PFC emulsion-treated dogs (Fig. 6). The in- 
crease in dissolved oxygen consumption was related 
to the dose of PFC emulsion. 
Significant differences were seen in Pvo 2 between 
the control and PFC emulsion groups at 0, 15, 30, 
and 45 minutes after CPB (Table IV). The Pvo2 
values measured 60 minutes after terminatiön of 
CPB in the control and PFC emulsion groups were 
insignificantly different (p = 0.099). This insignifi- 
cant difference at 60 minutes after CPB occurred 
contemporaneously with a decrease in blood PFC 
content in all three PFC groups. The differences in 
Pvo2 between control and PFC emulsion-treated 
animals at 0 through 45 minutes after CPB could not 
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Fig. 3. Pvo2 expressed as a function of CPB flow was higher (p < 0.05) in the 2.7 and 5.4 gm. kg -1 PFC 
emulsion dose groups than in the control group. Pvo2 in the range of 25 to 30 mm Hg represents he level 
below which oxygen transfer rates into tissues begin to decrease. The addition of a PFC emulsion to the 
perfusate allows a lower CPB flow rate before this range is entered. PFC-HIGH, PFC 1.35 gin. kg -1 (n = 
10 dogs); PFC-MID, PFC 2.7 gm. kg -1 (n = 10 dogs); PFC-LOW,, PFC 5.4 gin. kg -1 (n = 10 dogs). There 
is considerable overlap of the PFC-MID and PFC-LOW data. 
be explained by post-CPB differences in cardiac 
index, hematocrit, arterial Po2, or arterial oxygen 
content. Consistent, albeit insignificant, differences 
in the coronary sinus Po2 were observed between the 
control and PFC emulsion groups (i.e., the coronary 
sinus Po2 was consistently higher in the PFC emul- 
sion groups) (Table IV). The cardiac AVO2 differ- 
ences during and after CPB were similar among the 
control and PFC emulsion-treated animals. 
Myocardial wet-to-dry ratios measured at the 
terminatJon of the study were similar between the 
four experimental groups (wet-to-dry ratios: control 
group, 0.81 _+ 0.002; PFC 1.35 gm. kg -1 group, 
0.82 _+ 0.003; PFC 2.7 gm" kg -~ group, 0.81 _ 0.003; 
and PFC 5.4 gin. kg -a group, 0.81 _+ 0.003). Blood 
and esophageal temperatures were similar between 
groups during the study. 
Diseussion 
Our model of hypothermic CPB in an anemic 
animal represents an extreme condition as evi- 
denced by the high post-CPB mortality rates in the 
control and lowest-dose PFC emulsion groups. Ox- 
ygen delivepy during CPB in this model is limited by 
flow (stagnation hypoxia), anemia (änemi¢ hypoxia), 
and an increase in hemoglobin oxygen affinity 
caused by hypothermia ( ffinity hypoxia). 
There are advantages to an experimental model 
that combines everal hypoxic stresses. First, it is 
clinically relevant because multiple hypoxic stresses 
also occur during CPB in human beings, although 
these stresses are less severe. Second, our model 
defeated the body's usual mechanisms of compen- 
sating for an individual hypoxic stress. This feature 
allowed us to detect the effect of PFC-dissolved 
oxygen on post-CPB mortality. 
The experimental model used in this study also 
has disadvantages. For instance, it is impossible to 
dissect out the effect of PFC-dissolved oxygen on 
individual hypoxic stresses during CPB because mul- 
tiple hypoxic stresses were operative simultaneously. 
Most important among these differentiations is de- 
fining the effect of dissolved oxygen on tissue oxy- 
genation in the setting of anemic hypoxia. This 
information is necessary to equate dissolved oxygen 
(i.e., Po 2 and PFC emulsion dose) with oxygen 
transported by hemoglobin. 
In this study, total body oxygen consumption was 
not increased by the addition of PFC-dissolved 
oxygen, although Pvo 2 during CPB was increased by 
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Fig. 4. Pvo 2 values for the four groups were expressed as a function of oxygen delivery. This analysis 
accounts for the effect of dissolved oxygen in the PFC emulsion-treated animals and any animal-to-animal 
variance in hemoglobin concentration. The b coelticients (i.e., slopes) were similar; however, there are 
higher a values (i.e., intercepts) for the three PFC emulsion-treated groups as compared with the control 
group (p value range 0.025 to 0.09 for individual PFC emulsion groups versus control group comparisons). 
PFC-HIGH, PFC 1.35 gm • kg -1 (n = 10 dogs); PFC-MID, PFC 2.7 gm • kg -1 (n = 10 dogs); PFC-LOW,, 
PFC 5.4 gm • kg -1 (n = 10 dogs). 
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Fig. 5. Pvo 2 values for PFC emulsion groups (PFCE) were combined and expressed as a function of 
oxygen delivery during CPB. PFC emulsion-treated groups had significantly higher (p < 0.05) Pvo 2 values 
than the control group. This finding suggests paring of hemoglobin-bound oxygen by dissolved oxygen. 
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Fig. 6. PFC concentrations i  blood were used to calculate PFC-dissolved oxygen consumption during the 
experiment. This value is expressed as a percentage ofthe total oxygen consumption on the ordinate. Vo» 
Total body oxygen consumption; Baseline, prehemodilution control value; AN//, prebypass control value 
after normovolemic hemodilution; Dose, administration f PFC emulsion to experimental groups; boxed 
area, time during which animals were undergoing CPB. 
Tab le  IV. PO 2 measured in mixed venous and coronary sinus blood samples after CPB compared in control 
animals and PFC emulsion-treated animals 
Po  2 (mm Hg) 
Groups T = 0 min T = 15 min T = 30 min T = 45 min T = 60 min 
Mixed venous control 
Mixed venous PFC emulsion 
Coronary sinus control 
Coronary sinus PFC emulsion 
31.5 ± 1.9 34.7 _+ 2.2 30.7 ± 5.1 30.1 -+ 1.2 31.9 ± 2.1 
38.4 ± 1.5" 40.0 _+ 1.4"~ 39.5 ± 1.6" 35.4 ± 1.2" 36.2 -+ 1.3 
27.0 -+ 2.6 27.6 ± 2.1 25.9 + 2.1 28.1 ± 2.3 26.1 -+ 1.8 
28.9 ± 1.3 30.4 -+ 1.1 29.9 ± 1.1 32.3 -+ 2.6 29.9 + 1.4 
Values are ex~pressed as mean -+ standard error of the mean. Mixed venous, Mixed venous blood samples; Coronary sinus, coronary sinus blood samples; T, 
time after CPB. 
*p < 0.05 control compared with PFC emulsion-treated animals 
"~p < 0.05 for 2.7 and 5.4 gm. kg -1 PFC emulsion group compared with control animals. 
the PFC emulsion in a dose-related fashion. An 
analysis Of tissue oxygen consumption in a Krogh 
cylinder, published previously by Biro, 8 provides an 
explanation for this phenomenon. Biro's model 
shows that as the dissolved oxygen content of blood 
increases, small regions of tissue hypoxia resolve 
and PVO21 increases even though total tissue oxygen 
consumption remains constant. 
Another way to view the importance of increasing 
the PVO 2 during CPB is to consider PVO 2 as a 
surrogate measure of global t i ssue  Po2  .9"13 Using 
this line of reasoning, we can conclude that increas- 
ing the perfusate-dissolved oxygen content during 
CPB increases tissue Po 2. If a Pvo2 range of 25 to 30 
mm Hg is assumed to represent he lowest Pvo 2 
consistent with adequate tissue oxygenation, the 
contribution of additional PFC-dissolved oxygen to 
maintaining adequate tissue oxygenation during 
7 8 2 Holman et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
September 1995 
10 
~.  8 
% 
o 
6 
v 
"~ 4 
o 
2 
Y 
Blood  (Hgb=7 g in /d l )  
ART p02=600 tor f  
VEN P02=45 tor f  
P lasma+PFCE _ 
0 i I • I 
O 1 O0 200 300 400 500 600 
PO 2 (mmHg) 
Fig. 7. Oxygen delivery and availability during CPB at 
38 ° C and pH 7.40. Conditions of this model include: 
hemoglobin (Hgb) content, 7 gm. dl-l; arterial (ART) 
Po2, 600 mm Hg; and mixed venous (VEN) Po2, 45 mm 
Hg. The arterial-venous difference for bound oxygen is 
2.3 ml oxygen per deciliter of perfusate, and the arterial- 
venous difference for plasma-dissolved oxygen is 1.7 ml 
oxygen per deciliter of perfusate. Adding PFC 5.4 
gm. kg -1 increases the solubility coefficient of oxygen in 
the plasma-PFC emulsion (PFCE) mixture from 0.003 
ml .d l - l .mm Hg ~ to 0.005 ml.dl-~.mm Hg -1 and 
increases the arterial-venous difference for dissolved oxy- 
gen to 2.8 ml oxygen per deciliter of perfusate. As the 
temperature of CPB decreases or as pH increases, the 
arterial-venous difference for hemoglobin-bound oxygen 
decreases because of a leftward shift of the oxyhemoglobin 
dissociation curve. In contrast, he arterial-venous differ- 
ence for dissolved oxygen increases as the temperature 
decreases. 
CPB can be equated with additional hemoglobin- 
bound oxygen or a higher pump flow (Figs. 3 and 4). 
The contribution of PFC-dissolved oxygen to sur- 
vival after separation from CPB was noted even 
though the total amount of PFC-dissolved oxygen in 
the blood was smaller than the total amount of 
hemoglobin-bound oxygen. The beneficial effect of 
PFC-dissolved oxygen is due, in part, to the highly 
efficient ransfer of dissolved oxygen to tissues. The 
finding that relatively small volumes of oxygen can 
have important effects on cardiac function also 
corroborates results of previously published studies. 
These studies demonstrated abrupt deterioration i
regional contractile function during progressive ane- 
mia in myocardium distal to a stenotic coronary 
artery. 14-17 This functional deterioration was re- 
versed by a small increment in blood oxygen con- 
tent. 17 
Our study shows that increasing the dissolved 
oxygen content of blood by using a PFC emulsion 
and a high Po 2 improves tissue oxygenation during 
CPB. There are two possible mechanisms for this 
effect. The first mechanism involves the mass trans- 
port of oxygen dissolved in a PFC emulsion. PFCs 
have extremely high solubility coefficients for oxygen 
and other gasses, and the total volume of oxygen 
carried in the dissolved state during CPB can be 
further increased by the appropriate choice of oxy- 
genator device to provide a consistently high arterial 
Po2 .3 The total dose of a PFC emulsion that can be 
given during CPB has a limit; however, this dose 
limitation is counterbalanced by the greater avail- 
ability of dissolved oxygen than of hemoglobin- 
bound oxygen for diffusive transport into tissue. 
Dissolved oxygen is not chemically bound to plasma 
water or the PFC emulsion. Thus utilization of 
dissolved oxygen by tissues is highly etticient (90% to 
95% consumption of arterial dissolved oxygen) (Fig. 
7). Furthermore, larger volumes of oxygen dissolve 
in watet and PFC emulsions as the temperature 
decreases, and the availability of this dissolved oxy- 
gen is not affected by changes in pH or temperature. 
The second mechanism by which PFC emulsions 
may improve tissue oxygenation is acceleration of 
oxygen diffusion from hemoglobin to tissues. This 
putative mechanism is based on a eonsideration of
diffusion barriers in the microcirculation. Plasma in 
capillaries forms a boundary layer around erythro- 
cytes. Smaller particles such as platelets and PFC 
emulsion particles tend to segregate from the eryth- 
rocytes into the plasma layer. Diffusion of oxygen 
across this boundary layer represents the greatest 
barrier to the passage of oxygen from hemoglobin to 
tissues. 18-2° One previously published report sug- 
gested that a PFC emulsion in blood accelerates the 
diffusion of oxygen from erythrocytes to tissues21; 
however, others have not been able to document 
this effect. In vitro studies that quantify the kinetics 
of oxyhemoglobin dissociation with or without a 
PFC emulsion in the surrounding fluid may resolve 
this question. 
This in vivo whole-animal study of oxygenation 
during CPB has limitations that should be recog- 
nized. The measurements of oxyhemoglobin satura- 
tion and oxyhemoglobin content by optical densi- 
tometry were imprecise because of the turbidity of 
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the PFC emulsion. This imprecision made it impos- 
sible to determine by direct measurement the por- 
tion of total oxygen consumption that was derived 
from hemoglobin-bound oxygen. Thus sparing of 
hemoglobin-bound oxygen by the increased elivery 
of PFC-dissolved oxygen coutd not be directly dem- 
onstrated. The data describing arterial and venous 
blood oxygen content were acquired by using a fuel 
cell (i.e., Lex-Oz-Con device) rather than by calcu- 
lations from blood gas and hemoglobin saturation 
measurements. The fuel cell data provided areliable 
basis for the inferences of this experiment. The 
various contributions of PFC-dissolved oxygen to 
total oxygen consumption were calculated from the 
following direct measurements: PFC concentration 
as measured by gas chromatography and arterial Po 2 
and Pvo 2 as measured on blood gas analysis. The gas 
chromatography and blood gas measurements are 
considered highly reliable. 
Total body oxygen consumption is a gross mea- 
sure that can miss potentially important regional 
variations in tissue oxygen consumption. 22 Similarly, 
the transcardiac AVO 2 difference cannot detect 
variations in regional myocardial oxygen delivery or 
consumption. Information regarding regional myo- 
cardial oxygen metabolism is crucial to understand- 
ing cardiac adaptation tohemodilution and the role 
of dissolved oxygen in preventing regional myocar- 
dial hypoxia. 
The Pv02 is an imperfect measure of tissue Po 2. It 
is insensitive to the regional heterogeneity of tissue 
Po 2 levels that exist within individual organs. Fur- 
thermore, the tissue Poz is always lower than the 
surrounding venous Po2; how rauch lower, however, 
is not known. 
We described oxygen metabolism in animals with 
normal hearts. Additional experiments that measure 
regional myocardial oxygen metabolism and me- 
chanical function will be necessary to define the 
limits of hemodilution in normal and diseased 
hearts. Most of the information currently available 
regarding adequate l vels of perfusate hemoglobin 
concentration during CPB was generated by empiric 
observations in patientsY -26 Currently no method 
exists to define the lowest acceptable hemoglo- 
bin concentration during CPB for individual pa- 
tients.27, 28 
It is possible that increasing the dissolved oxygen 
content of blood will be especially beneficial in 
diseased hearts. This benefit is primarily because the 
viscosity of blood is increased less by the addition of 
a PFC emulsion than by the addition of erythro- 
cytes 29 and because dissolved oxygen is more avail- 
able than hemoglobin-bound oxygen for diffusive 
transport into tissues. Keipert and colleagues 3° have 
published similar observations on the availability of 
dissolved oxygen in a study that examined oxygen 
consumption during profound normovolemic he- 
modilution in a canine model that did not include 
CPB. 
This study examined tissue oxygenation during 
CPB with use of graded concentrations of dissotved 
oxygen. Graded increases in Pv02 were observed in 
response to graded increases in the dissolved oxygen 
content of blood. Dissolved oxygen was useful in 
ameliorating post-CPB cardiac failure. These data 
suggest that dissolved oxygen is an effective tempo- 
rary substitute for hemoglobin-bound oxygen during 
CPB and that dissolved oxygen may be particularly 
beneficial in the setting of multiple hypoxic stresses. 
PFC emulsions used in combination with a high Po 2 
during CPB may diminish the need for allogeneic 
erythrocyte ransfusions. 
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Appendix 1 
The first step in comparing oxygen consumption be- 
tween groups was to summarize the data with an equation 
that expresses total body oxygen consumption as a func- 
tion of CPB flow or oxygen delivery. The total body 
oxygen consumption data were described by the equation 
for a rectangular hyperbola, 31
a.x  
ru2  - b + x 
The variable x in the equation was either pump flow 
normalized to body surface area or the total oxygen 
delivered to the body (i.e., the x-axis variables). Ifx is very 
large (x » b), the equation tends to a. Thus, the parameter 
a is the maximum value of the equation, which in this case 
is the maximum oxygen consumption. 
The equation that was chosen is consistent with the 
physiology of the experimental model and produced cor- 
relation coefficients (i.e., r a values) >0.50. As CPB flow or 
oxygen delivery increases, total body oxygen consumption 
asymptotically approaches a maximum value. The b pa- 
rameter determines the fraction of maximum oxygen 
consumption at any given x. This equation was used 
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previously by Fox and associates 31 to describe total body 
oxygen consumption during CPB in human beings. 
The parameters of the equation were calculated for 
each animal by using the nonlinear egression procedure 
of aAS.  4 The data from one animal regressed poorly (r 2 < 
0.50), and this study was excluded. The calculated param- 
eters a and b were compared between groups by using 
Duncan's multiple-range t st and a least-squares means 
test: The mean values of a and b for each experimental 
group were calculated and used to produce the plots of 
total body oxygen consumption as a function of CPB flow 
or oxygen delivery. 
The variance in the rectangular hyperbola equations 
was calculated by using the following equation: 
oy Var(a) +(~b)2 Var(b) gar (y )  = (~äa)2 • 
Oy Oy Cov(ab) 
+2. oä " 07" 
where y is total body oxygen consumption. The 70% 
confidence intervals on the graphs were obtained by using 
the square root of this equation (---1 SD*). 
Similar methods were used to determine the optimal 
curve fit and variance for the Pvo• (see Appendix 2), 
lactate, and hemoglobin oxygen saturation data. The 
*Standard eviation~ 
parameters of the equations were then compared by using 
Duncan's multiple-range t st and a least-squares means 
test. 
Appendix 2 
For the Pv% data, the equation that best fit the data was 
one describing exponential growth: 
Pvo2 = a + e »x - 1. 
The variable x represents either normalized CPB flow or 
oxygen delivery. By subtracting i from the right side of the 
equation, a becomes the y-axis intercept (i.e., the Po e 
value as x approaches zero). Because by definition x _> 0, 
the a value atx = 0 is the minimum value of the equation. 
Although anx value of zero is unrealistic in an experimen- 
tal system, the a value calculated for x = 0 is useful for 
between-group comparisons. The a value quantifies verti- 
cal shifts in the curves that describe Pvo 2 as a function of 
CPB flow or oxygen delivery. The b parameter describes 
the slope of the curve. A larger b in the equation means 
that the Po2 increases more for a given increase in x than 
if b is a smaller number. 
The mean values of a and b for each experimental group 
were calculated and used to produce the plots of Pvo a as a 
function of CPB flow or oxygen delivery. The data were 
analyzed by using a nonlinear regression procedure in SAS, 7 
followed by between-group comparisons ofa and b that used 
Duncan's multiple-range t st and a least-squares means test. 
